Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II clinical trial studies how well craniospinal irradiation (CSI) with hippocampal avoidance, using proton therapy or volumetric modulated arc therapy (VMAT), works in treating patients with breast cancer or non-small cell lung cancer (NSCLC) that has spread from the original (primary) tumor to the cerebrospinal fluid (CSF) and meninges (thin layers of tissue that cover and protect the brain and spinal cord) (leptomeningeal metastases). Radiation therapy is an effective treatment in relieving localized symptoms caused by leptomeningeal metastases. However, the type of radiation therapy typically used does not prevent the spread of leptomeningeal disease. CSI (radiation therapy directed at the brain and spinal cord to kill tumor cells) may be able to target all of the areas of possible leptomeningeal tumor spread. CSI may however result in significant neurological side effects due to radiation damage to a part of the brain called the hippocampus. Hippocampal avoidance (HA) reduces the amount of radiation to the hippocampus. Proton or VMAT CSI with HA may be an effective treatment while reducing neurological side effects for patients with leptomeningeal metastases from breast cancer and NSCLC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi lub niedrobnokomórkowy rak płuca z przerzutami do opon mózgowo-rdzeniowych
- •Kwalifikacja do radioterapii tych przerzutów
- •Wiek od 18 lat
- •Odpowiedni stan sprawności
- •Zdolność wyrażenia świadomej zgody
- •Prawidłowe wyniki badań krwi
- •Odpowiedni status płodności/antykoncepcji
✗ Disqualifies
- •Poważne deficyty neurologiczne, w tym encefalopatia
- •Rozległa choroba systemowa bez rozsądnych opcji leczenia
- •Niemożność wykonania rezonansu mózgu i kręgosłupa z kontrastem
- •Wcześniejsza radioterapia uniemożliwiająca bezpieczne powtórne leczenie
- •Rozległa choroba komór mózgu
- •Przerzuty do mózgu blisko hipokampu, nieleczone wcześniej
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
University of California San Francisco
San Francisco, United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, United States
Trial contact
Lia M. Halasz
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.